Published April 2023
| Version v1
Journal article
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
Creators
- Rousset, Perrine
- Dalle, Stéphane
- Mortier, Laurent
- Dereure, Olivier
- Dalac, Sophie
- Dutriaux, Caroline
- Leccia, Marie-Thérèse
- Legoupil, Delphine
- Brunet-Possenti, Florence
- de Quatrebarbes, Julie
- Grob, Jean-Jacques
- Saiag, Philippe
- Maubec, Eve
- Stoebner, Pierre-Emmanuel
- Granel-Brocard, Florence
- Arnault, Jean-Philippe
- Allayous, Clara
- Oriano, Bastien
- Lebbé, Celeste
- Montaudié, Henri
Contributors
Others:
- Centre Hospitalier Universitaire de Nice (CHU Nice)
- Centre Léon Bérard [Lyon]
- Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Pathogenesis and Control of Chronic and Emerging Infections (PCCEI) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]-Université de Montpellier (UM)
- Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Service de Dermatologie (CHU de Dijon) ; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
- CHU Bordeaux [Bordeaux]
- Centre Hospitalier Universitaire [Grenoble] (CHU)
- Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
- AP-HP - Hôpital Bichat - Claude Bernard [Paris] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
- Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM] ; Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)
- Hôpital Ambroise Paré [AP-HP]
- Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
- Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay
- Hôpital Avicenne [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM) ; CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Service de Dermatologie et Allergologie [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
- CHU Amiens-Picardie
- Service de Dermatologie [AP-HP Hôpital Saint-Louis] ; Hopital Saint-Louis [AP-HP] (AP-HP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
- Hopital Saint-Louis [AP-HP] (AP-HP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Hôpital Hôtel-Dieu [Paris] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Service de Dermatologie [Nice] ; Hôpital Archet 2 [Nice] (CHU)
- Centre méditerranéen de médecine moléculaire (C3M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)
Description
Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.Objective: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP).Methods: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed.Results: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type.Limitations: No record of standard diagnostic criteria of MUP used in the participating centers.Conclusions: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04052676
- URN
- urn:oai:HAL:hal-04052676v1
Origin repository
- Origin repository
- UNICA